In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Seth Lederman, co-founder, CEO and chairman of Tonix Pharmaceuticals. Seth and Mike explored the two programs Tonix are currently developing in pain and psychiatry, areas where many larger companies have turned their back due to subjective endpoints. Tonix believes they have developed invaluable expertise to counter these challenges and Seth explains that the difficul...
Nov 18, 2020•32 min•Season 1Ep. 15
In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Sanjay Kakkar, CEO of San Francisco Bay-based start-up Tranquis Therapeutics. The company focuses on neurodegenerative diseases, an area where significant unmet medical need remains and that has presented the life sciences sector with major challenges for many years. Undaunted, Tranquis Therapeutics has successfully raised $30m in series A for their lead compound. In ...
Nov 18, 2020•22 min•Season 1Ep. 14
In response to the pandemic, governments around the world have instituted policy changes intended to mitigate the impact of the coronavirus that could have long-lasting impacts. In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership talks to DRG market access experts Steve Edgar and Judith Rubinstein about how new policies are reshaping supply chains, testing, development, approval and care delivery – and what it means for life sciences executives. Hosted on...
Nov 18, 2020•40 min•Season 1Ep. 13
In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Richard Erwin, General Manager and Managing Director of Roche Products Ltd (UK). Mike and Richard discuss what companies can learn from the pandemic and if the business world will operate the same way as before. Richard shared how they sped up their clinical trial lead time, from initial discussions through to first patient, to under a month (normally this could take ...
Nov 17, 2020•43 min•Season 1Ep. 12
In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Mark Stevenson, Vice President and Chief Operations Officer at Thermo Fisher Scientific. Mark talks to Mike about day-to-day pandemic effects on operations and priorities, and how they have redistributed resources to help combat impact and maintain longer-term business focus. He also explores how he feels the pandemic will change supply chains moving forward, as well ...
Nov 17, 2020•32 min•Season 1Ep. 11
In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Eric Elenko, Chief Innovation Officer of PureTech. Eric provides a unique insight into how they use a problem centric approach to identify and build out treatment programs, both internally and through their own founded entities. Eric also explains how this model has inspired them to repurpose one of their existing programs, LYT-100, to help solve the issue of pulmonar...
Nov 17, 2020•34 min•Season 1Ep. 10
In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Daphne Zohar, Founder and CEO of PureTech. Daphne sheds light on how their unique and innovative business model looks to solve unmet needs and problem areas across the industry, how they differ from your typical biotech and the benefit of their problem centric approach. She explores how they’re constantly innovating their internal pipeline and adapting to the needs of...
Nov 17, 2020•30 min
In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Baroness Susan Greenfield, founder and CEO of Oxford-based start-up Neuro-bio. Susan and Mike discuss the impacts of COVID-19 in the workplace and how the new stay-at-home policy has put a pause on projects. As a member of the House of Lords, Susan was also able to explore and share her views on the dynamics between politicians and science. Hosted on Acast. See acast....
Nov 17, 2020•28 min•Season 1Ep. 8
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership talks to Christian Hogg, Executive Director and CEO of Chi-Med, about how the pharmaceutical and biotech industry in China has shifted its priorities from generic medicines to more innovative therapies. Christian talks in depth around the driving factors and investment in innovation, including a reform of the regulatory environment and the vast expansion of access to patients. He also gives his take on w...
Nov 17, 2020•30 min•Season 1Ep. 7
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership talks to Steve Fruchtman, President and CEO of Onconova Therapeutics Inc, about how the reallocation of resources within cancer centres around the world due to COVID-19. Steve talked us through the impacts on their early and late stage lead programs which includes short term restrictions such as accessing review data, as well as longer-term impacts including additional monitoring and testing for patients...
Nov 17, 2020•29 min
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership talks to John Jaeger, a partner at DRG on how COVID-19 is disrupting access to care. John talks us through the results from a recent physician survey, about current limitations on access to treatment including how patients are responding to the shift from in-facility treatment to home-administered treatments. John and Mike also discuss the implications of the “warehousing” effect that will take place and...
Nov 17, 2020•27 min•Season 1Ep. 5
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG talks to Dr. RJ Tesi, CEO of INmune Bio about its clinical program that seeks to determine whether its existing TNF inhibitors can be repurposed to prevents complications of cytokine storm caused by COVID-19. Dr. Tesi gives solemn insight into trial design, endpoint selection, FDA application as well explaining how INmune is “messing” with the pathology of COVID-19, not only to treat its symptoms ...
Nov 14, 2020•41 min•Season 1Ep. 4
In this episode of Conversations in healthcare, Mike Ward, Global Head of Thought Leadership talks to Dana Gheorghe, Ph.D, Associate Director, Oncology, about the impact COVID-19 is having on treatment for already available CAR T-cell therapies as well as those being developed. Dana gives us the lay of the land in an area where there is scarcity of information that is frequently changing. Dana covers how patients are being prioritised according to risk and need at this time and the challenges of...
Nov 13, 2020•26 min•Season 1Ep. 3
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership talks to Christian Hogg, CEO of Hutchison China MediTech about how the organisation has tackled the impacts of COVID-19 on business globally. Christian gives us a month-by-month account from January to May of how they mitigated disruption and moved to a place of “new normal”, most notably within business activities related to commercial operations and getting vital medication to patients on clinical tria...
Nov 13, 2020•27 min•Season 1Ep. 2
In this episode of Conversations in Healthcare, Mike Ward talks to Werner Lanthaler, CEO of Evotec, about how COVID-19 is bringing pharma leaders together and giving them collaborative momentum. Dr. Lanthaler is a co-founding member of COVID R&D, a global pharma industry initiative that has come together to rapidly respond to the pandemic. Together they are fast-tracking learnings and protocols to create a toolbox that can accelerate activities like clinical trials, re-purposing compounds an...
Nov 13, 2020•33 min•Season 1Ep. 1
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership speaks with Bryan Witherbee, President & CEO of Adarza BioSystems. Earlier this year, Adarza raised 25 million dollars to support the full commercialization of Ziva, an automated biological platform which delivers comprehensive, high definition, protein biomarker profiles. Although their launch plans were disrupted by the pandemic, Bryan shares how Adarza responded to the challenge by utilizing Ziva ...
Oct 02, 2020•35 min•Season 1Ep. 1
